120108-62-5 Usage
Uses
Used in Pharmaceutical Synthesis:
3-Chloro-phenylalanine hydrochloride is utilized as a key intermediate in the pharmaceutical industry for the synthesis of peptide-based drugs. Its incorporation into these drugs aids in the treatment of a wide range of diseases and disorders, highlighting its importance in medicinal chemistry.
Used in Antibiotic Development:
In the field of antibiotic research, 3-Chloro-phenylalanine hydrochloride is explored for its potential to contribute to the development of novel antibiotics. Its unique properties make it a promising candidate for creating new classes of antibiotics to combat drug-resistant bacteria.
Used in Antiviral Agent Development:
3-Chloro-phenylalanine hydrochloride is also under investigation for its possible applications in the development of antiviral agents. Its role in this context is to help create new treatments for viral infections, potentially offering new therapeutic options for patients.
Used in Drug Discovery:
As a valuable chemical building block, 3-Chloro-phenylalanine hydrochloride is employed in drug discovery processes. Its versatility and reactivity in chemical synthesis make it instrumental in the creation of biologically active molecules, which are essential for advancing medical research and treatment options.
Check Digit Verification of cas no
The CAS Registry Mumber 120108-62-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,1,0 and 8 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 120108-62:
(8*1)+(7*2)+(6*0)+(5*1)+(4*0)+(3*8)+(2*6)+(1*2)=65
65 % 10 = 5
So 120108-62-5 is a valid CAS Registry Number.
120108-62-5Relevant academic research and scientific papers
Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"
Varnavas, Antonio,Lassiani, Lucia,Valenta, Valentina,Mennuni, Laura,Makovec, Francesco,Hadjipavlou-Litina, Dimitra
, p. 563 - 581 (2007/10/03)
In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.
